Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Oncotelic Therapeutics (OTLC) Stock Price & Analysis

OTLC Stock Chart & Stats

$0.02-$0.00(-11.11%)
At close: 4:00 PM EDT
$0.02$0.03$0.043 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$0.02 - $0.03
52-Week Range
$0.02 - $0.11
Previous Close
$0.02
Volume
458.46K
Average Volume (3M)
473.40K
Market Cap
$7.48M
Enterprise Value
$33.45M
Total Cash (Recent Filing)
$186.01K
Total Debt (Recent Filing)
$13.89M
Price to Earnings (P/E)
0.0
Beta
-0.03
Next Earnings
Apr 19, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

AI-driven Oncology Discovery

The PLA framework gives Oncotelic a data-driven approach to oncology discovery, using large literature and biological datasets to identify research signals. Expansion through autonomous AI agents and extensive protein vectors could improve productivity and broaden the company’s future development pipeline.

Moderate Recent Leverage

Moderate recent leverage provides some solvency support and may reduce immediate balance-sheet pressure while the company develops its candidates. A less stressed capital structure can preserve flexibility for research spending, although historical leverage volatility means this benefit is not yet fully established.

Collaborative Research Platform

The BIO REBOOT initiative could expand Oncotelic’s research ecosystem beyond its internal resources by attracting outside projects and potential collaborators. Greater platform participation may generate additional scientific opportunities, strengthen visibility in oncology research, and support future partnership formation.

Bears Say

Minimal And Inconsistent Revenue

Minimal and inconsistent revenue indicates that Oncotelic has not yet demonstrated a durable commercial base for its business model. This limits operating scale, makes results difficult to forecast, and leaves future progress dependent on successful development, partnering, or other non-recurring sources.

Persistent Cash Burn

Sustained negative operating and free cash flow means the company is not funding research and operations internally. Continued cash burn can force recurring external financing, constrain development priorities, and weaken financial resilience if additional capital becomes harder or more dilutive to obtain.

Convertible Financing Dilution Risk

The convertible note provides near-term funding but can increase the share count through discounted or variable-price conversion, while adding interest and repayment obligations. Reliance on this structure may dilute existing holders and reflects continuing financing pressure during the development period.

Oncotelic Therapeutics News

OTLC FAQ

What was Oncotelic Therapeutics’s price range in the past 12 months?
Oncotelic Therapeutics lowest stock price was $0.02 and its highest was $0.11 in the past 12 months.
What is Oncotelic Therapeutics’s market cap?
Oncotelic Therapeutics’s market cap is $7.48M.
When is Oncotelic Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Oncotelic Therapeutics’s earnings last quarter?
Oncotelic Therapeutics released its earnings results on Aug 24, 2026. The company reported $0.001 earnings per share for the quarter.
Is Oncotelic Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Oncotelic Therapeutics pay dividends?
Oncotelic Therapeutics does not currently pay dividends.
What is Oncotelic Therapeutics’s EPS estimate?
Oncotelic Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncotelic Therapeutics have?
Oncotelic Therapeutics has 457,512,800 shares outstanding.
What happened to Oncotelic Therapeutics’s price movement after its last earnings report?
Oncotelic Therapeutics reported an EPS of $0.001 in its last earnings report. Following the earnings report the stock price went down -5.405%.
Which hedge fund is a major shareholder of Oncotelic Therapeutics?
Currently, no hedge funds are holding shares in OTLC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology